Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.

Graydon S MeneillyChristine Roy-DuvalHasan AlawiGeorge DaileyDiego BellidoCarlos TrescoliHelard Manrique HurtadoHailing GuoValerie PilorgetRiccardo PerfettiHamish Simpsonnull null

Published in: Diabetes care (2017)

In nonfrail older patients uncontrolled on their current antidiabetic treatment, lixisenatide was superior to placebo in HbA1c reduction and in targeting postprandial hyperglycemia, with no unexpected safety findings.

Keyphrases

physical activity
randomized controlled trial
type diabetes
oxidative stress
mesenchymal stem cells
skeletal muscle
cancer therapy
study protocol